培美曲塞联合奥沙利铂治疗肺癌的疗效与机制研究

Mechanism of pemetrexed combined with oxaliplatin in regulating NOD1/NF-κB/R1P2 signaling in lung cancer

摘要:

目的 研究培美曲塞联合奥沙利铂调控NOD1/NF-κB/R1P2信号治疗肺癌的机制。方法 选取2014年1月—2017年1月天津市第五中心医院收治的晚期肺腺癌患者80例。随机分为两组：观察组接受培美曲塞联合奥沙利铂化疗；对照组接受培美曲塞联合顺铂化疗。化疗2个疗程后评价疗效和不良反应，采用酶联免疫吸附试验（ELISA）检测患者血清NOD1、NF-κB、R1P2及Caspase-3蛋白含量；采用实时聚合酶链反应（real-time PCR）检测肺腺癌组织NOD1、NF-κB、R1P2及Caspase-3 mRNA表达。结果 观察组培美曲塞联合奥沙利铂化疗的效果优于对照组（P?<0.05）；观察组培美曲塞联合奥沙利铂化疗的不良反应与对照组比较，差异有统计学意义（P?<0.05），观察组低于对照组；与化疗前比较，化疗后观察组和对照组患者血清NOD1、NF-κB、R1P2和Caspase-3蛋白含量升高，癌组织NOD1、NF-κB、R1P2及Caspase-3 mRNA表达升高（P?<0.05）；与对照组比较，观察组患者血清NOD1、NF-κB、R1P2及Caspase-3蛋白含量升高，癌组织NOD1、NF-κB、R1P2及Caspase-3 mRNA表达升高（P?<0.05）。结论 培美曲塞联合奥沙利铂治疗肺腺癌与联合顺铂比较，其疗效更高、不良反应更小，其机制可能与调控NOD1/NF-κB/R1P2信号有关。

Abstract:

Objective To investigate the mechanism of the combination of pemetrexed and oxaliplatin in the treatment of lung cancer by regulating NOD1/NF-κB/R1P2 signaling. Methods Eighty patients with lung adenocarcinoma admitted to our hospital from January 2014 to January 2017 were enrolled and randomized into two groups. Patients in the observation group received the treatment of pemetrexed combined with oxaliplatin and the control group received the treatment of pemetrexed combined with cisplatin. The therapeutic effects and adverse reactions were evaluated after 2 cycles of chemotherapy. The serum NOD1, NF-κB, R1P2, and Caspase-3 protein levels were detected by using ELISA method. The mRNA expressions of NOD1, NF-κB, R1P2 and Caspase-3 in the lung adenocarcinoma tissues were determined by using Real-Time PCR approach. Results The efficacy of pemetrexed combined with oxaliplatin in chemotherapy was higher than that of control group (P?